Analytical Data
-
基因名
VACWR087
- Application
-
别名
(Protein F1)
-
种属
Vaccinia virus
-
表达系统
Yeast
-
标签
C- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07611
-
表达区间
2-319aa
-
分子量
37.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR087 is a recombinant protein derived from the Vaccinia virus, which has garnered significant interest in the field of immunology and vaccine development. This protein is believed to play a critical role in modulating the host's immune response, thereby enhancing the understanding of viral pathogenesis and the development of effective therapeutics. The Vaccinia virus, being a member of the Orthopoxvirus genus, has been widely studied due to its historical use as a live vaccine against smallpox and its potential for use in oncolytic virology. Research on VACWR087 focuses on its interactions with host immune mechanisms, particularly how it may inhibit inflammatory pathways or manipulate cellular responses to improve viral survival and replication. Additionally, the potential application of VACWR087 in novel vaccine platforms offers a promising avenue for developing vaccines against other infectious diseases and cancers. Ongoing studies aim to elucidate the detailed biochemical pathways influenced by VACWR087, advancing both basic virology and translational medicine. This research not only contributes to the understanding of the Vaccinia virus but may also pave the way for innovative strategies in immune modulation and therapeutic interventions.
